摘要
["Background: About 75% of newly diagnosed bladder cancer cases suffer from non-muscle invasive bladder cancer (NMIBC), which used to recur and progress despite transurethral resection of bladder tumor (TURBT). This meta-analysis was conducted to examine if combined application of intravesical bacille Calmette-Guerin (BCG) with chemotherapy is associated with better prognosis.","Methods: Systematic searches of randomized controlled trials (RCTs) concerning NMIBC were performed in PubMed, EMbase, CENTRAL, CNKI, WanFang, VIP, CBM databases, and some specializedwebsites. Two researchers independently implemented study selection, quality assessment and data extraction. Hazard ratios (HRs) and their 95% confidence intervals (CIs) for treatment effects on recurrence-free survival (RFS), progression-free survival (PFS), overall survival (OS) and disease-specific survival (DSS) were directly extracted, if available, or estimated using relevant data from included studies. Side effects, such as fever, gastrointestinal reaction, cystitis, irritative bladder symptoms and hematuria, were also extracted as outcome measurements, and associated relative risks (RRs) were calculated to assess treatment safety. RevMan 5.3 software was used to perform statistical analyses.","Results: Thirteen RCTs containing 1,754 patients with NMIBC were included in this meta-analysis. Compared with BCG alone, the combination therapy significantly improved RFS (HR = 0.53, 95% CI: 0.43-0.66, P < 0.01), OS (HR = 0.66, 95% CI: 0.50-0.86, P = 0.002), and DSS (HR = 0.48, 95% CI: 0.29-0.80, P = 0.005). While PFS showed no obvious difference between combination therapy and BCG alone (HR = 0.65, 95% CI: 0.25-1.68, P = 0.38). The rate of fever (RR = 0.50, 95% CI: 0.27-0.91, P = 0.02), irritative bladder symptoms (RR = 0.69, 95% CI: 0.52-0.90, P = 0.007) and hematuria (RR = 0.50, 95% CI: 0.28-0.89, P = 0.02) were significantly decreased in patients treated with combination therapy compared to those with BCG alone. There were no statistically significant differences between combination therapy and BCG alone in toxicity (RR = 0.69, 95% CI: 0.34-1.40, P = 0.30), gastrointestinal reaction (RR = 2.54, 95% CI: 0.61-10.60, P = 0.20) or cystitis (RR = 0.67, 95% CI: 0.29-1.54, P = 0.34).","Conclusions: Combined application of intravesical BCG and chemotherapy appears to be an effective treatment for patients with intermediate-to high-risk NMIBC, but not for those with tumor in situ alone or recurrent bladder cancer."]
| 源语言 | 英语 |
|---|---|
| 期刊论文编号 | 121 |
| 页数 | 13 |
| 期刊 | FRONTIERS IN ONCOLOGY |
| 卷 | 9 |
| DOI | |
| 出版状态 | 已出版 - 1 3月 2019 |
联合国可持续发展目标
此成果有助于实现下列可持续发展目标:
-
可持续发展目标 3 良好健康与福祉
关键词
- non-muscle invasive bladder cancer
- bacille Calmette-Guerin
- chemotherapy
- prognosis
- meta-analysis
收录
- SCIE
- Scopus
学术指纹
探究 'Combination of Intravesical Bacille Calmette-Guerin and Chemotherapy vs. Bacille Calmette-Guerin Alone in Non-muscle Invasive Bladder Cancer: A Meta-Analysis' 的科研主题。它们共同构成独一无二的学术指纹。引用此
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver